Abstract: The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.

Abstract: The invention provides for devices and methods for interfacing microchips to cartridges and pneumatic manifolds. The cartridges, microchips, and pneumatic manifolds can be integrated with downstream preparation devices, such as thermal regulating devices and separation and analysis devices.

Abstract: A method to achieve controlled conductivity in microfluidic devices, and a device formed thereby. The method comprises forming a microchannel or a well in an insulating material, and ion implanting at least one region of the insulating material at or adjacent the microchannel or well to increase conductivity of the region.

Abstract: System, including methods, apparatus, and kits, for detection of nucleic acids.

Abstract: A method to achieve controlled conductivity in microfluidic devices, and a device formed thereby. The method comprises forming a microchannel or a well in an insulating material, and ion implanting at least one region of the insulating material at or adjacent the microchannel or well to increase conductivity of the region.

Abstract: A microfluidic system and method for employing it to control fluid temperatures of fluids residing within microchannels of a microfluidic device. The microfluidic device is provided with a top layer and a bottom layer and microchannels configured therebetween. Temperature of the fluid within the microchannels is controlled in various ways including the use of electrical resistive heating elements and by providing zones located in contact with the top and bottom layers of the microfluidic device for circulating heat transfer of fluid therein.

Abstract: Methods and systems for effecting a parameter and detecting a parameter using two electric signal in a conductive path are described.

Abstract: Devices, assemblies, systems and methods described herein enable detection of as few as a single copy of a target nucleic acid molecule. Polynucleotides copied from a single or a small number of target nucleotide(s) within regions near to an initial copying site may be detected by optical or other methods as disclosed herein. Devices, assemblies and systems may comprise probes and/or primer molecules. Systems comprising optical assemblies, thermal assemblies and reaction assemblies (having reaction chambers for amplification of target nucleic acid molecules) are provided in which used reaction assemblies may be replaced to provide reusable devices. Systems comprising analytical assemblies and detection assemblies are provided in which an assay cartridge having assay chambers may engage a thermal assembly for amplification of target nucleic acid molecules. These devices, systems and methods offer the advantages of detection of as few as a single copy of a target nucleic acid molecule.

Abstract: Methods and systems for effecting a parameter and detecting a parameter using two electric signal in a conductive path are described.

Abstract: Methods and systems for effecting a parameter and detecting a parameter using two electric signal in a conductive path are described.

Abstract: The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.

Abstract: The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth.

Abstract: Methods and systems for effecting a parameter and detecting a parameter using two electric signal in a conductive path are described.

Abstract: A process for the production of essentially homogeneous soluble, stable, endotoxin free human recombinant interleukin-1.alpha. of enhanced specific activity is described. The process involves breaking transformed microbial cells containing expressed human interleukin-1.alpha. and separating the soluble supernatant from the insoluble cell components and then passing the supernatant through gel chromatography and ion-exchange chromatography steps.

Abstract: The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.

Abstract: The oligoribonucleotide analogs of the invention are relatively small, three-dimensional structures derived from larger parental RNA molecules. The analogs include a first nucleic acid structure including one or more nucleotide sequences that are derived from a region of parental RNA, wherein in its native state, the region binds to a ligand, e.g., an aminoglycoside, with a parental RNA ligand binding pattern, and a second nucleic acid structure including one or more nucleotide sequences combined with the first nucleic acid structure to form the analog and provide the analog with a conformation that binds the ligand with a ligand binding pattern that is substantially identical to the parental RNA ligand binding pattern. These analogs can be used to identify novel therapeutic compounds.

Abstract: Disclosed is a method for the inhibition of binding of a ligand to an RNA, the inhibition being mediated by a small organic molecule which binds to the RNA, thereby inhibiting ligand binding. A preferred class of small organic molecules are the 2-deoxystreptamine (2-DOS) aminoglycosides. Disclosed herein are members of the 2-DOS class that are useful for the inhibition of binding of Rev to an RNA containing an RRE. In an HIV infected cell, a consequence of the inhibition of the ability of Rev to bind to the RRE in HIV encoded transcripts is inhibition of HIV replication.